Michael Ryskin
Stock Analyst at B of A Securities
(1.11)
# 2,218
Out of 4,479 analysts
29
Total ratings
43.75%
Success rate
-10.89%
Average return
Main Sectors:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $7.12 | +33.43% | 1 | Jun 25, 2024 | |
| EXAI Exscientia | Downgrades: Neutral | $11 → $9 | $5.15 | +74.76% | 2 | Jan 5, 2024 | |
| MRVI Maravai LifeSciences Holdings | Upgrades: Buy | $10 → $8 | $6.94 | +15.27% | 2 | Dec 12, 2023 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $13.64 | +75.95% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $20.77 | +15.55% | 2 | Jul 31, 2023 | |
| ALGN Align Technology | Maintains: Underperform | $190 → $225 | $238.64 | -5.72% | 5 | Apr 27, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $172.58 | +4.30% | 6 | Nov 4, 2022 | |
| OMIC Singular Genomics Systems | Downgrades: Underperform | $90 | $8.52 | +956.34% | 3 | Aug 10, 2022 | |
| IDXX IDEXX Laboratories | Downgrades: Neutral | $550 → $470 | $476.40 | -1.34% | 1 | May 5, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $7.46 | - | 1 | Apr 18, 2022 | |
| SDGR Schrödinger | Downgrades: Neutral | n/a | $18.76 | - | 2 | Nov 11, 2021 | |
| ABSI Absci | Downgrades: Underperform | n/a | $3.01 | - | 2 | Nov 10, 2021 |
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $7.12
Upside: +33.43%
Exscientia
Jan 5, 2024
Downgrades: Neutral
Price Target: $11 → $9
Current: $5.15
Upside: +74.76%
Maravai LifeSciences Holdings
Dec 12, 2023
Upgrades: Buy
Price Target: $10 → $8
Current: $6.94
Upside: +15.27%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.64
Upside: +75.95%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $20.77
Upside: +15.55%
Align Technology
Apr 27, 2023
Maintains: Underperform
Price Target: $190 → $225
Current: $238.64
Upside: -5.72%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $172.58
Upside: +4.30%
Singular Genomics Systems
Aug 10, 2022
Downgrades: Underperform
Price Target: $90
Current: $8.52
Upside: +956.34%
IDEXX Laboratories
May 5, 2022
Downgrades: Neutral
Price Target: $550 → $470
Current: $476.40
Upside: -1.34%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.46
Upside: -
Schrödinger
Nov 11, 2021
Downgrades: Neutral
Price Target: n/a
Current: $18.76
Upside: -
Absci
Nov 10, 2021
Downgrades: Underperform
Price Target: n/a
Current: $3.01
Upside: -